skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi Team, Sorry about just copying this info, but RBC is doing a better job than I could:
12:23 PM EDT, 05/03/2017 (MT Newswires) -- RBC Capital is initiating coverage on TSO3 with an Outperform, Speculative Risk rating and C$4.25 target. TSO3 has recently commercialized a proprietary and highly differentiated device for the sterilization of medical devices, particularly endoscopes, in healthcare settings, the brokerage reports, adding that the company is therefore uniquely positioned with its marketing partner, Getinge (a world leader in infection control sales). "We expect greater than ~40% returns over the next 12-months."
Price: 3.17, Change: +0.08, Percent Change: +2.6
Would you agree or disagree with RBC on TSO3?
Thanks, Chris
Read Answer Asked by Chris on May 08, 2017
Q: Just a follow up on the question today about healthy menu companies, I might suggest Ten Peaks as well. Decaf coffee sales are on the rise and the Swiss Water Process ( ie Ten Peaks) is regarded as the premier method. Their 1st Q earnings come out next week so we will have a better idea of business at that time.
Read Answer Asked by Murray on May 05, 2017
Q: The shares of PYR have moved up today and a company with the symbol HPQ announce it has ordered a second phase of Process Characterization Testing from PyroGenesis; alas, the HPQ in question is not Hewlett-Packard but a much smaller company "HPQ Silicon Resources" which is listed in Frankfurt and on the TSX-Venture exchange.

What can you tell us about this TSX.V-listed HPQ and is its announced relationship with PYR meaningful for the continuing progress of Pyrogenesis Canada?

Thanks to the 5i team for their informative insights.
Read Answer Asked by Steve on May 05, 2017
Q: CHH has issued a press release of their signing a New 5-year Credit Facilities for Completion of Debt Refinancing Plan. The reduction in borrowing costs from $26.4M in 2015 to a pro-forma of $4.5M along with a reduction in their weighted average interest rate from 6.7% to 5.25% is impressive. Would you please provide your assessment of this company and also comment if it time to buy this stock? Thanks Gordon
Read Answer Asked by Gordon on May 05, 2017
Q: Would you consider Acuityads to be a worthy addition to a growth portfolio? Thanks again
Read Answer Asked by Seamus on May 04, 2017
Q: I have been watching this micro cap (Eurocontrol Technics - EUO)for awhile now. After the sale of one of their technologies early last year the company is now trading at approximately cash / cash equivalents on the balance sheet and it boasts some interesting imagery & composition technology in the semiconductor measurement space which is just entering the commercial stage. The technology seems somewhat aligned with Photon Controls business which has done wonders. Would this be an interesting business combination? What do you think of EUO as a micro cap speculation for high risk capital?

Thanks
Read Answer Asked by Scott on May 03, 2017
Q: I've been interested in NXO lately due to the market activity so I did a bit of research on the technology itself. The theory of flat lenses and the proof of concept that it works was discovered by Federico Capasso and his team at Harvard University. When their research paper was first published, Federico Capasso was contacted by one of the world's largest smartphone manufactures (which means they are now working on it). Since then many of the research team members have been picked off by various universities and companies world wide to develop it's potential further.
The point is (NXO) Nexoptic did not invent the technology of their prototype lens system.
So investors beware that NXO really has nothing proprietary, nor do they have the size and scale of potential competitors. The idea that an iPhone will someday have Nexoptic lenses is probably a bit of a stretch. The best outcome I see is that their telescope patent (if approved) is sold to a larger manufacturer, which is not going to make the average investor any money over the next 5 years.
I hope I'm wrong and wish them luck!

Shane
Read Answer Asked by SHANE on May 02, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!